Sign in
AVXL Stock Price, Chart, Stats & News
Anavex Life Sciences Corp.
Save
231.22M
Market cap
–
Current P/E
1.54x
Forward P/E
AVXL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.05% |
ROA | -30.04% |
ROE | -38.76% |
D/E | – |
Interest coverage ratio | – |
AVXL valuation
P/E | – |
P/S | – |
P/B | 1.98x |
P/CF | -7.37x |
P/FCF | -7.67x |
P/OCF | -7.37x |
PEG | -0.42x |
EV multiple | -9.83x |
About
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
Similar securities
Based on sector and market capitalization
Report issue